CD274 and renal pelvis/ureter urothelial carcinoma: A third limitation is the study's retrospective design and the absence of patients who received immune checkpoint blockade therapy, which preclude any conclusions regarding whether PD‐L1 and platelet count are predictive biomarkers in UTUC.